SQLite Web: event_store.db

Update row 1077 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-07T23:23:54.391414+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:f6962788ffe1993d","evidence_event_ids":["evt_40b50f2c3b41"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1630627/0001630627-26-000005.txt","as_of":"2026-04-07T23:23:54.391414+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1630627/0001630627-26-000005.txt","company":"TREACE MEDICAL CONCEPTS, INC.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1630627/0001630627-26-000005.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_a88f993065c483ff","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1630627/0001630627-26-000005.txt","content_type":"text/plain","enriched_at":"2026-04-07T23:42:46.604054+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"DEF 14A","final_url":"https://www.sec.gov/Archives/edgar/data/1630627/0001630627-26-000005.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1630627/0001630627-26-000005.txt","source_event_id":"evt_40b50f2c3b41","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEF 14A","fp":"98aa9ec5291376e8","kind":"sec_filing","published_at":"20260406","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-06","2026-05-19","2015-01-01 (late 2015 referenced)","2021-01-01 (introduced Adductoplasty in 2021)","2018-01-01 (Surgeon Advisory Board published paper in 2018)","2025-01-01 (2025 Key Accomplishments referenced)"],"entities":[{"asset_class":"equity","name":"Treace Medical Concepts, Inc.","relevance":"high","symbol":"","type":"issuer"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal (no prior filing comparison content included).","No specific agenda items, director nominees, or voting proposals are included in the provided text excerpt.","The SEC filing number, amendment number, and whether any amendment occurred are not shown (Amendment No. is blank in the excerpt).","No financial guidance or financial implications are disclosed in the provided excerpt beyond corporate/product updates."],"key_facts":["Form type: DEF 14A (Schedule 14A) definitive proxy statement.","Filing date shown in the document: April 6, 2026 (letter dated April 6, 2026).","Meeting date/time: Tuesday, May 19, 2026 at 11:00 a.m. Eastern Time.","Meeting format: live webcast.","Webcast/meeting access URL: www.virtualshareholdermeeting.com/TMCI2026.","Stockholders may vote before the meeting by regular mail, telephone, or online, and may vote online during the meeting.","The proxy statement references \u201c2025 Key Accomplishments\u201d and states the company offers solutions for all four bunion classes.","The document states Lapiplasty\u00ae System has \u201cover 134,000 patients treated since late 2015.\u201d","The document states Nanoplasty\u00ae 3D Minimally Invasive Bunion Correction System and Percuplasty\u2122 Percutaneous 3D Bunion Correction System were fully commercially available in the second half of 2025.","The document states SpeedMTP\u00ae System began full commercial release in the second half of 2025."],"numeric_claims":[{"label":"Annual meeting date","value":"2026-05-19"},{"label":"Annual meeting time (ET)","value":"11:00 a.m."},{"label":"Lapiplasty patients treated","value":"over 134,000"},{"label":"Lapiplasty since","value":"late 2015"},{"label":"Commercial availability (Nanoplasty/Percuplasty)","value":"second half of 2025"},{"label":"Commercial release (SpeedMTP)","value":"second half of 2025"}],"primary_claim":"Treace Medical Concepts, Inc. filed a definitive proxy statement (DEF 14A) on April 6, 2026 for its 2026 Annual Meeting of Stockholders to be held May 19, 2026 at 11:00 a.m. Eastern Time via live webcast.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Treace Medical Concepts, Inc. filed a definitive proxy statement on Schedule 14A (DEF 14A) for its 2026 Annual Meeting of Stockholders. The filing invites stockholders to attend a May 19, 2026 live webcast meeting and highlights 2025 accomplishments and product/system updates.","topics":["SEC filing","DEF 14A","proxy statement","annual meeting","stockholder voting","corporate updates","product portfolio"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEF 14A \u00b7 TREACE MEDICAL CONCEPTS, INC. \u00b7 Filed 20260406","ticker":"TMCI","tickers":["TMCI"],"title":"TMCI filed DEF 14A","url":"https://www.sec.gov/Archives/edgar/data/1630627/0001630627-26-000005.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel